Evecare • Vol 11 • No. 2 • Sep–Dec 2023 8 Product Profile Dear Doctor, If you prescribe Evecare forte™ (Liquid, Tablet) and Reosto® (Tablet) and would like to share your feedback, please write to us at publications@himalayawellness.com Thank you! The Editor—Evecare, Scientific Publications Division HimalayaWellness Company, Makali, Bengaluru 562162, Karnataka, India Product Feedback Reosto® (TABLET) Restores bone health Reosto, a phytopharmaceutical formulation, is recommended for the treatment of senile and postmenopausal osteoporosis, and in immobilized patients following bone fracture. The elemental calcium in Reosto helps increase bone mineral density (BMD) and serum calcium levels. Reosto inhibits bone resorption, favorably inf luences bone formation, increases bone mass, and prevents the risk of osteoporotic fractures. Composition Each Reosto Tablet contains: Pdrs. Guggulu (Commiphora wightii) 235 mg Godanti bhasma 120 mg Rasna (Pluchea lanceolata) 50 mg Bala (Sida cordifolia) 45 mg Arjuna (Terminalia arjuna) 45 mg Ashvagandha (Withania somnifera) .45 mg Kukkutandatvak bhasma 35 mg Processed in Vamsa (Bambusa arundinacea), Kumari (Aloe vera), and Dhanyaka (Coriandrum sativum). Clinical Pharmacology Reosto promotes remineralization of bones; exerts phytoestrogenic, calcium supplementation, antiinf lammatory, antioxidant, and adaptogenic actions; and controls associated risk factors. Reosto restores the increased level of alkaline phosphatase (indicating its beneficial effect on bone formation), and decreases the urinary excretion of pyridinoline, deoxypyridinoline, and hydroxyproline (indicating inhibition of bone resorption). Thus, Reosto inhibits bone resorption and favorably inf luences bone formation. Indications • Osteoporosis – Senile osteoporosis – Postmenopausal osteoporosis • Immobilization following fractures Dosage 2 Tablets twice daily, followed by 1 tablet twice daily as maintenance dose. Adverse Effects No adverse effects have been reported. Contraindications No known contraindications. Drug Interactions No significant drug interactions have been reported. Presentation Box of 2 blister-pack strips of 30 tablets each.
RkJQdWJsaXNoZXIy MjAwNDg=